Form 4: Intellia Therapeutics CEO John Leonard Reports Stock Transactions
SEC Form 4 Filing
John Leonard, CEO of Intellia Therapeutics, reports the vesting of restricted stock units and related transactions.
Summary
- On January 1, 2025, John Leonard, the President and CEO of Intellia Therapeutics, had restricted stock units convert into 7,850 shares of common stock.
- Following the transaction, Leonard directly owns 967,922 shares of common stock.
- Leonard also indirectly owns 58,415 shares through a trust.
- The reported transaction involves restricted stock units granted on March 3, 2021, which vest in installments.
Sentiment
Score: 5
Explanation: This is a neutral filing, simply reporting required information about stock transactions. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common for publicly traded companies. It provides transparency to investors regarding the holdings and transactions of company insiders.
Comparison to Industry Standards
- Executive compensation packages often include restricted stock units that vest over time, aligning executive interests with long-term shareholder value.
- The vesting schedule of 25% initially and then annual installments is a common practice.
- Similar filings are made by executives at comparable biotech companies like CRISPR Therapeutics and Editas Medicine, reflecting standard compensation practices in the industry.
Stakeholder Impact
- Shareholders are informed about the stock transactions of a key executive, providing transparency.
- The vesting of RSUs aligns the executive's interests with the long-term performance of the company.
Key Dates
| Date | Description |
|---|---|
| 2021-03-03 | Reporting person was granted 31,394 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. |
| 2022-01-01 | 25% of the RSU vesting. |
| 2024-11-04 | Date of Limited Power of Attorney execution. |
| 2025-01-01 | Restricted stock units convert into common stock; 7,850 shares acquired. |
| 2025-01-03 | Date of Form 4 signature. |
| 2031-03-02 | Expiration date of the Restricted Stock Unit. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.